Table 4.

Atorvastatin acid pharmacokinetic parameters

	AUC0–8 (ng*h/mL)			C max (ng/mL)			Tmax (h)
Patient	Baseline	Ratio short term/baseline	Ratio long term/baseline	Baseline	Ratio short term/baseline	Ratio long term/baseline	Baseline	Ratio short term/baseline	Ratio long term/baseline
Gastric bypass
9	9	2.3	1.0	2.3	2.0	0.8	1.1	2.7	2.6
10	14	1.2	1.7	5.3	0.7	1.8	0.6	0.8	4.9
8	17	2.2	0.8	4.0	2.2	1.0	2.7	0.2	1.1
7	19	1.1	1.4	5.0	0.7	1.3	0.7	1.7	4.5
5	35	1.8	1.6	5.7	3.0	1.8	5.9	0.3	1.0
12	37	1.5	1.0	8.7	1.3	0.8	1.1	2.7	2.7
3	42	1.1	0.7	7.6	1.6	1.5	0.8	3.8	3.8
2	43	0.8	0.5	7.1	1.0	0.8	1.0	0.8	0.6
1	63	1.0	0.3	10.5	1.5	0.3	1.3	2.5	3.9
6	138	0.5	0.3	33.0	0.6	0.4	1.0	0.5	2.4
11	163	0.4	0.4	117.4	0.2	0.2	1.0	1.5	2.8
4	315	0.3	0.3	133.7	0.2	0.4	1.6	1.9	0.7
Mean ± SD	74 ± 90	1.2 ± 0.7	0.8 ± 0.5	28 ± 46	1.3 ± 0.8	0.9 ± 0.6	1.6 ± 1.5	1.6 ± 1.1	2.6 ± 1.5
Duodenal switch
3	14	1.9	1.2	3.9	1.5	1.2	0.9	3.4	1.1
4	17	1.8	1.7	2.8	2.3	2.1	2.5	0.8	0.3
8	18	2.0	0.8	3.1	2.6	1.5	1.8	0.3	0.5
10	25	3.4	0.4	6.3	6.2	0.4	0.6	5.5	1.8
5	38	1.3	0.3	7.8	1.8	0.3	0.6	5.6	14.5
1	44	1.0	0.3	15.9	0.5	0.3	0.6	3.6	2.5
2	53	4.2	ND	13.5	4.2	ND	0.5	6.0	ND
6	89	1.9	ND	24.2	1.6	ND	2.4	1.3	ND
9	133	1.6	0.5	42.6	1.0	0.4	0.5	1.3	4.1
7	153	1.4	0.6	78.5	0.8	0.2	1.4	2.2	3.5
Mean ± SD	59 ± 59	2.0 ± 1.0	0.7 ± 0.5	20 ± 24	2.2 ± 1.7	0.8 ± 0.7	1.2 ± 0.8	3.0 ± 2.1	3.5 ± 4.7

AUC _0–8 area under the plasma concentration versus the time curve from 0 to 8 h postdose, C _max maximum plasma concentration, T _max time to reach C_max, SD standard deviation, ND Not Done